Joel S. Schuman, MD, FACS, highlights home tonometry, virtual visual fields, and portable OCT devices as promising tools, ...

AND JESS, YOU SAY THIS COULD BE A GAME CHANGER. YOU KNOW, IT REALLY CAN. ABOUT 3 MILLION AMERICANS HAVE GLAUCOMA AND THIS NEW TREATMENT IS BASICALLY AN IMPLANTABLE DRUG FOR THE EYE. AND DOCTORS SAY IT ...

Smith, MD, of Glaucoma Associates of Texas, in Dallas, sat down with the Eye Care Network to reflect on how glaucoma care ...

Looking back, glaucoma specialists like Dr. Christine Funke of Barnet Dulaney Perkins Eye Center can remember a time not long ago when treatment options for the eye condition were greatly limited.

Shared insight on how the use and sequencing of therapies for glaucoma will evolve in coming years. Neil Minkoff, MD: Where do we see glaucoma therapy going in the next 24 to 36 months, due to ...

Glaucoma, the silent thief of sight, damages the optic nerve without early symptoms, leading to irreversible vision loss.

In matched cohorts of more than 41,000 patients each, use of tirzepatide was linked to a significantly reduced risk of primary open-angle glaucoma compared with selective GLP-1 receptor agonists (risk ...

Please provide your email address to receive an email when new articles are posted on . “Glaucoma medication is associated with changes in meibomian glands morphology, including decreased acinar area, ...

Please provide your email address to receive an email when new articles are posted on . Glaucoma-related ocular surface disease is a significant and often underdiagnosed ocular comorbidity that can ...

Glaucoma causes vision loss by damaging the optic nerve. This leads to loss of peripheral vision and eventually blindness. The damage to the optic nerve is multifactorial, but increased ocular ...

Glaucoma is a term that refers to a group of eye diseases that cause damage to the optic nerve. This nerve damage can lead to vision loss and blindness. Since glaucoma is asymptomatic in its early ...